We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Moderna Announces Agreement with Sanofi for Fill/Finish Manufacturing of COVID-19 Vaccine
Product News

Moderna Announces Agreement with Sanofi for Fill/Finish Manufacturing of COVID-19 Vaccine

Moderna Announces Agreement with Sanofi for Fill/Finish Manufacturing of COVID-19 Vaccine
Product News

Moderna Announces Agreement with Sanofi for Fill/Finish Manufacturing of COVID-19 Vaccine

Credit: torstensimon/ Pixabay

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Moderna Announces Agreement with Sanofi for Fill/Finish Manufacturing of COVID-19 Vaccine"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, has announced that it has entered into an agreement with Sanofi (Nasdaq: SNY) for fill/finish sterile manufacturing services and supply packaging for up to 200 million doses of the Moderna COVID-19 Vaccine in the U.S. beginning in September 2021. Sanofi will leverage its established manufacturing infrastructure at its site in Ridgefield, NJ.


“We welcome the opportunity to work with Sanofi on fill/finish manufacturing for the Moderna COVID-19 Vaccine in the U.S. We would like to thank the Department of Health and Human Services and the Biden Administration for their assistance in securing this additional capacity,” said Juan Andres, Moderna’s Chief Technical Operations and Quality Officer. “This additional production will help us continue to scale up our manufacturing capacity in the United States.”

Advertisement